Cvs Triple-thick Antibacterial Washcloths
Loading...Cvs Triple-thick Antibacterial Washcloths Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
For external use only.
- deep or puncture wounds
- animal bites
- serious burns
- do not get into eyes
- irritation or redness develops
- conditions persist for more than 72 hours
If swallowed, get medical help or contact a Poison Control Center right away.
- deep or puncture wounds
- animal bites
- serious burns
- irritation or redness develops
- conditions persist for more than 72 hours
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
- helps reduce germs that can potentially cause infection
History
There is currently no drug history available for this drug.
Other Information
There are no additional details available for this product.
Sources
Cvs Triple-thick Antibacterial Washcloths Manufacturers
-
Cvs Pharmacy
![Cvs Triple-thick Antibacterial Washcloths (Benzalkonium Chloride) Cloth [Cvs Pharmacy]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Cvs Triple-thick Antibacterial Washcloths | Teva Pharmaceuticals Usa Inc
Use the lowest effective dose for the patient.
2.1 Dosage in AdultsThe recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. In some patients, the higher morning blood levels of eszopiclone tablets following use of the 2 mg or 3 mg dose increase the risk of next day impairment of driving and other activities that require full alertness [see Warnings and Precautions (5.1)]. The total dose of eszopiclone tablets should not exceed 3 mg, once daily immediately before bedtime [see Warnings and Precautions (5.6)].
2.2 Geriatric or Debilitated PatientsThe total dose of eszopiclone tablets should not exceed 2 mg in elderly or debilitated patients.
2.3 Patients with Severe Hepatic Impairment, or Taking Potent CYP3A4 InhibitorsIn patients with severe hepatic impairment, or in patients coadministered eszopiclone tablets with potent CYP3A4 inhibitors, the total dose of eszopiclone tablets should not exceed 2 mg [see Warning and Precautions (5.7)].
2.4 Use with CNS DepressantsDosage adjustments may be necessary when eszopiclone tablets are combined with other CNS depressant drugs because of the potentially additive effects [see Warnings and Precautions (5.1)].
2.5 Administration with FoodTaking eszopiclone tablets with or immediately after a heavy, high-fat meal results in slower absorption and would be expected to reduce the effect of eszopiclone tablets on sleep latency [see Clinical Pharmacology (12.3)].
Login To Your Free Account